iShares Core MSCI Emerging Markets ETF vs Regeneron Pharmaceuticals Inc — how do they compare? iShares Core MSCI Emerging Markets ETF trades at $79.42, while Regeneron Pharmaceuticals Inc trades at $672.86 (market cap $70.47B). The key difference: Regeneron Pharmaceuticals Inc pays a 0.56% dividend while iShares Core MSCI Emerging Markets ETF pays none, and iShares Core MSCI Emerging Markets ETF is trading nearer its 52-week high, Regeneron Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| IEMG | REGN | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $86.00 | $812.27 |
52-Week Low | $59.90 | $545.46 |
Market Cap | — | $70.47B |
Enterprise Value | — | $64.42B |
Dividend Yield | — | 0.56% |
Signals from Pluang's Aura AI — not financial advice
IEMG trades at $77.21, up 0.3% with a bearish technical signal from moving averages and oscillators. The ETF shows strong recent performance with 35% gains over the past year, driven by emerging market inflows and AI-focused technology exposure. Recent news highlights record capital flows into emerging markets and IEMG's 40% technology weighting, though some analysts caution about elevated volatility and concentration risks.
The outlook remains mixed with attractive emerging market valuations and growth opportunities balanced against geopolitical risks and market volatility. Key catalysts include continued AI-driven technology performance and emerging market economic growth, while risks involve US-China tensions and potential market corrections given the ETF's recent strong run.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
IEMG tracks the MSCI Emerging Markets Investable Market Index, providing broad exposure to large, mid, and small-cap stocks across over 20 emerging market countries. It is designed as a low-cost core holding for investors seeking diversified growth from economies outside of developed markets.
Read more on IEMG →Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →